Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bo Dupont

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood|February 28, 2002
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursorsGuenther Koehne, Katherine M Smith, Teresa L Ferguson, et al.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics|October 14, 2003
[Killer Ig-like receptor gene content diversity and haplotype analysis in Chinese Han population in Shanghai]Lei Zhang, Katharine C Hsu, Xiao-Rong Liu, et al.
Blood|February 26, 2005
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypesKatharine C Hsu, Carolyn A Keever-Taylor, Andrew Wilton, et al.
The New England Journal of Medicine|November 20, 2014
Donor activating KIR2DS1 in leukemiaJeffrey M Venstrom, Bo Dupont, Katharine C Hsu, et al.
The New England Journal of Medicine|August 31, 2012
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1Jeffrey M Venstrom, Gianfranco Pittari, Ted A Gooley, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2003
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesSacha Gnjatic, Djordje Atanackovic, Elke Jäger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastomaJeffrey M Venstrom, Junting Zheng, Nabila Noor, et al.
The Journal of Clinical Investigation|August 7, 2012
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatmentNidale Tarek, Jean-Benoit Le Luduec, Meighan M Gallagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach, Sacha Gnjatic, Paul Sabbatini, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancyKatharine C Hsu, Ted Gooley, Mari Malkki, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood|February 28, 2002
Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursorsGuenther Koehne, Katherine M Smith, Teresa L Ferguson, et al.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi = Zhonghua Yixue Yichuanxue Zazhi = Chinese Journal of Medical Genetics|October 14, 2003
[Killer Ig-like receptor gene content diversity and haplotype analysis in Chinese Han population in Shanghai]Lei Zhang, Katharine C Hsu, Xiao-Rong Liu, et al.
Blood|February 26, 2005
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypesKatharine C Hsu, Carolyn A Keever-Taylor, Andrew Wilton, et al.
The New England Journal of Medicine|November 20, 2014
Donor activating KIR2DS1 in leukemiaJeffrey M Venstrom, Bo Dupont, Katharine C Hsu, et al.
The New England Journal of Medicine|August 31, 2012
HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1Jeffrey M Venstrom, Gianfranco Pittari, Ted A Gooley, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2003
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responsesSacha Gnjatic, Djordje Atanackovic, Elke Jäger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastomaJeffrey M Venstrom, Junting Zheng, Nabila Noor, et al.
The Journal of Clinical Investigation|August 7, 2012
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatmentNidale Tarek, Jean-Benoit Le Luduec, Meighan M Gallagher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remissionCatherine S M Diefenbach, Sacha Gnjatic, Paul Sabbatini, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancyKatharine C Hsu, Ted Gooley, Mari Malkki, et al.
Pageof 4